MX2018004041A - Tratamiento de trastornos de acidos biliares. - Google Patents

Tratamiento de trastornos de acidos biliares.

Info

Publication number
MX2018004041A
MX2018004041A MX2018004041A MX2018004041A MX2018004041A MX 2018004041 A MX2018004041 A MX 2018004041A MX 2018004041 A MX2018004041 A MX 2018004041A MX 2018004041 A MX2018004041 A MX 2018004041A MX 2018004041 A MX2018004041 A MX 2018004041A
Authority
MX
Mexico
Prior art keywords
bile acid
signaling pathway
long acting
fgf21
treatment
Prior art date
Application number
MX2018004041A
Other languages
English (en)
Inventor
Xu Jing
Stanislaus Shanaka
Hsiu M Chen Mei-
H Hale Clarence
Veniant-Ellison Murielle
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2018004041A publication Critical patent/MX2018004041A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se refiere a un método de tratar un paciente que lo necesita con un agonista de acción prolongada a la vía de señalización FGF21. En una modalidad particular, la invención se refiere al uso de moléculas que estimulan la vía de señalización de FGF21, tales como polipéptidos de FGF21 de acción prolongada o anticuerpos agonistas, para tratar trastornos o enfermedades asociadas con el ácido biliar en exceso. La invención se refiere además a formulaciones farmacéuticas y dosificación de agonistas de acción prolongada de la vía de señalización de FGF21 adecuada para tratar trastornos relacionados con el ácido biliar.
MX2018004041A 2015-10-01 2016-09-30 Tratamiento de trastornos de acidos biliares. MX2018004041A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562236050P 2015-10-01 2015-10-01
PCT/US2016/055017 WO2017059371A1 (en) 2015-10-01 2016-09-30 Treatment of bile acid disorders

Publications (1)

Publication Number Publication Date
MX2018004041A true MX2018004041A (es) 2018-11-09

Family

ID=57145043

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018004041A MX2018004041A (es) 2015-10-01 2016-09-30 Tratamiento de trastornos de acidos biliares.

Country Status (8)

Country Link
US (1) US20180280474A1 (es)
EP (1) EP3355908A1 (es)
JP (1) JP2018529729A (es)
AU (1) AU2016332062A1 (es)
CA (1) CA3000697A1 (es)
MA (1) MA42985A (es)
MX (1) MX2018004041A (es)
WO (1) WO2017059371A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116098989A (zh) 2018-02-08 2023-05-12 广东东阳光药业有限公司 Fgf21变体、融合蛋白及其应用
US11427623B1 (en) 2019-05-28 2022-08-30 89Bio Ltd. Methods of treatment using mutant FGF-21 peptide conjugates
TW202140525A (zh) * 2020-01-08 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 Ｆｇｆ２１突變體蛋白及其融合蛋白
CN115322794A (zh) 2020-01-11 2022-11-11 北京质肽生物医药科技有限公司 Glp-1和fgf21的融合蛋白的缀合物

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
EP0088046B1 (de) 1982-02-17 1987-12-09 Ciba-Geigy Ag Lipide in wässriger Phase
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0154316B1 (en) 1984-03-06 1989-09-13 Takeda Chemical Industries, Ltd. Chemically modified lymphokine and production thereof
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
DE3889853D1 (de) 1987-11-05 1994-07-07 Hybritech Inc Polysaccharidmodifizierte Immunglobuline mit reduziertem immunogenem Potential oder verbesserter Pharmakokinetik.
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
ATE135370T1 (de) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemisch modifizierte granulocytenkolonie erregender faktor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU633698B2 (en) 1990-01-12 1993-02-04 Amgen Fremont Inc. Generation of xenogeneic antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
US5234784A (en) 1992-04-01 1993-08-10 Eastman Kodak Company Method of making a projection viewable transparency comprising an electrostatographic toner image
NZ255101A (en) 1992-07-24 1997-08-22 Cell Genesys Inc A yeast artificial chromosome (yac) vector containing an hprt minigene expressible in murine stem cells and genetically modified rodent therefor
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
AU2010246038A1 (en) * 2009-05-05 2011-12-01 Amgen Inc. FGF21 mutants and uses thereof
DK3248610T3 (da) * 2009-05-05 2024-01-15 Amgen Inc Fgf21-mutanter og anvendelser deraf
AU2012301769B2 (en) * 2011-08-31 2016-05-19 Amgen Inc. FGF21 for use in treating type 1 diabetes
CN108888757A (zh) * 2012-12-27 2018-11-27 恩格姆生物制药公司 用于调节胆汁酸体内稳态及治疗胆汁酸紊乱和疾病的方法

Also Published As

Publication number Publication date
WO2017059371A1 (en) 2017-04-06
US20180280474A1 (en) 2018-10-04
EP3355908A1 (en) 2018-08-08
AU2016332062A1 (en) 2018-04-26
JP2018529729A (ja) 2018-10-11
MA42985A (fr) 2018-08-22
CA3000697A1 (en) 2017-04-06

Similar Documents

Publication Publication Date Title
PH12018500586A1 (en) Farnesoid x receptor agonists and uses thereof
PH12019502058A1 (en) Farnesoid x receptor agonists and uses thereof
PH12020500286A1 (en) Use of agonists of formly peptide receptor 2 for treating ocular inflammatory diseases
UY39119A (es) Proteínas de fusión para tratar trastornos metabólicos
PH12018502538A1 (en) Antibodies to alpha-synuclein and uses thereof
PH12016501809A1 (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2019007834A (es) Composiciones para modular la expresion de c9orf72.
EA201692109A1 (ru) Варианты антител к фактору d и их применение
NZ751746A (en) Combination therapy with controlled-release cnp agonists
MX2017016134A (es) Aril dihidro-2h-benzo[b][1,4]oxazina sulfonamida y compuestos relacionados para uso como agonistas de rory y el tratamiento de enfermedad.
EA201790802A1 (ru) Соединения против tnf
PH12021550605A1 (en) Farnesoid x receptor agonists and uses thereof
MX2018000352A (es) 4-azaindoles sustituidos y su uso como moduladores del receptor glun2b.
MX2018004041A (es) Tratamiento de trastornos de acidos biliares.
MX2017002364A (es) Terapia de combinacion para tratamiento de cancer.
MD20160007A2 (ro) Inhibitori ai RORC2 şi metode de utilizare a acestora
MX2018015110A (es) Arn modificado que codifica polipeptidos de vegf-a. formulaciones y usos relacionados con los mismos.
EA201691567A1 (ru) Способы лечения легких травм головного мозга
EA201792571A1 (ru) Терапевтическое применение l-4-хлорокинуренина
MX2017007054A (es) Composiciones y métodos para usar solabegron de liberación modificada para sintomas del tracto urinario inferior.
CR20210499A (es) Compuestos y composiciones como moduladores de la señalización de tlr
MX2020009566A (es) Compuestos como moduladores de la se?alizacion de tlr2.
MX2017009608A (es) Compuestos anticancerigenos.
GB2537783A (en) Methods and compositions used in treating inflammatory and autoimmune diseases
MX2017006491A (es) Composiciones y métodos para la modulación de la actividad at2r.